Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 save search
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
Published: 2021-10-15 (Crawled : 15:00) - globenewswire.com
ATRX | $0.0067 1724.82% 12K
|
Manufacturing
|
| O: 10.47%
H: 19.05%
C: 14.29%
disease phase 2 parkinson trial phase 2b
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
Published: 2023-03-29 (Crawled : 13:00) - biospace.com/
BIXT A | $0.146 490.75% 120K
|
Professional, Scientific, and T...
|
| O: 0.1%
H: 7.14%
C: 4.76%
positive trial results phase 2
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 4.43%
H: 6.71%
C: -1.41%
trial phase 3 phase 1 phase 2 enroll
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
Published: 2021-01-28 (Crawled : 22:01) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 26.04%
H: 22.52%
C: -3.93%
fda trial phase 3 phase 1 phase 2 clinical hold
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
| Email alert
Add to watchlist
phase 2 chronic cough
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
Published: 2021-11-19 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.5%
stroke phase 1 positive phase 2 phase 3
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: -0.93%
pharmaceuticals trial agreement depression study phase 2
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -4.93%
conference study phase 2
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 1.48%
H: 8.75%
C: 6.25%
fibrosis study phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
Published: 2023-06-06 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 8.43%
H: 2.28%
C: 2.28%
conference pharmaceuticals phase 2
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 3.1%
H: 0.94%
C: -3.21%
drug group pharmaceuticals program phase 2
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
Published: 2023-08-08 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: -7.67%
H: 0.0%
C: 0.0%
drug stroke study phase 2
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Published: 2021-12-08 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 3.62%
H: 10.26%
C: 0.87%
phase 2 drug stroke
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
Published: 2021-12-02 (Crawled : 16:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: -0.28%
H: 0.14%
C: -5.57%
phase 2 trial chronic cough enroll
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 1.33%
H: 1.73%
C: -14.06%
als trial approval stroke phase 1 phase 2 phase 3
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -4.78%
fda phase 2 als phase 2b positive chronic cough
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.77%
stroke phase 1 phase 2
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Published: 2021-10-08 (Crawled : 12:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: -7.45%
H: 16.61%
C: 11.3%
fda phase 2 chronic cough
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.